Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Quentin30 is a pathological prevaricator.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(67)
•••
Comment by Quentin30on Apr 15, 2024 10:40am
57 Views
Post# 35989273

RE:RE:RE:Quentin30 is a pathological prevaricator.

RE:RE:RE:Quentin30 is a pathological prevaricator.Let's see how well today's panel discussion works out for ONCY shall we... 

I speak of cold chain storage requirements, and you dismiss this as a non-concern. Really??? How on earth do you know what clinics will be used..?? oh dear oh dear.

Still, you somehow feel the need to cast me as the villain here... muah hahaa...

Whilst you have been pumping and touting buyout and partnership for the past 3 years at least..  and where IS said partnership... even Bracelet-1 coupled with a CPI is now a thing of the past...

Perhaps you can fool many on the BB that ONCY is a sure bet, but longer term holders have heard the same dog and pony show for far too long to be so easily swayed..


What have you got to say for yourself about accerlated approval..??? the same as Matt or Dr Heineken have said... i.e. nothing..??? 

LOL... you are ridiculous
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities